[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369768-105":59,"doc-detail-369768-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","carg-2020-targets-il-12-il-17-and-pd-l1-pathways-to-effectively-treat-melanoma-and-breast-cancer","CARG-2020 targets IL-12, IL-17, and PD-L1 pathways to effectively treat melanoma and breast cancer","","Cancer immunotherapy is effective only for some tumor types, motivating new strategies that combine oncolytic viruses with immune modulators. CARG-2020 is an engineered trivalent oncolytic construct expressing IL-12 together with shRNAs that inhibit IL-17RA signaling and regulate PD-L1 expression. The study evaluates systemic intravenous delivery of CARG-2020 and shows control of colorectal cancer growth in mice, alongside efficacy in melanoma and triple-negative breast cancer models. Treatment increases intratumoral CD8+ T lymphocyte accumulation, and T-cell depletion weakens tumor regression, supporting broad antitumor activity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/carg-2020-targets-il-12-il-17-and-pd-l1-pathways-to-effectively-treat-melanoma-and-breast-cancer/369768/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/carg-2020-targets-il-12-il-17-and-pd-l1-pathways-to-effectively-treat-melanoma-and-breast-cancer/369768.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is CARG-2020 and what immune pathways does it target?","Question",{"text":112,"@type":113},"CARG-2020 is an engineered trivalent oncolytic viral construct that expresses IL-12 and uses shRNAs to inhibit IL-17RA signaling and regulate PD-L1 expression, thereby modulating multiple anti-tumor immune pathways.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was CARG-2020 administered in the study, and what was the reported effect?",{"text":117,"@type":113},"CARG-2020 was delivered systemically via the intravenous route. The study reports successful control of tumor growth in mouse models, including melanoma and triple-negative breast cancer, in addition to colorectal cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"Why do CD8+ T lymphocytes matter for CARG-2020 efficacy?",{"text":121,"@type":113},"Administration of CARG-2020 increases accumulation of CD8+ T lymphocytes in tumors. Depleting these T cells results in poor tumor regression, indicating CD8+ T cells are important for the therapeutic effect.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369768,1790588953,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCARG-2020 targets IL-12, IL-17, and PD-L1 pathways to effectively treat melanoma and breast cancer  \nElham Ahmadi1,2,4, Conner Chiari1,4, Bhaskara Reddy Madina2, Timur OlegovichYarovinsky2, Marie Marthe Krady2, Ju Chen1,3, Bijan Almassian2, Valerian Nakaar2 & Kepeng Wang1􀀍  \nCancer immunotherapy has recently achieved a breakthrough status, however, it is not effective in all cancer types. Genetically engineered oncolytic viruses (OVs) with immunomodulators are promising new therapeutic modalities for cancer. CARG-2020 is an engineered trivalent oncolytic viral construct that specifically expresses three immune modulators that inhibit IL-17RA signaling and regulate PD-L1 expression by shRNAs, along with the cytokine IL-12 which activates multiple tumoricidal pathways. Previous work showed that intratumoral (i.t.) injection ofCARG-2020 exhibits robust efficacy against established colorectal cancer (CRC). In this study, we report that systemic delivery ofCARG-2020 via the intravenous (i.v.) route can successfully control CRC growth. To further expand the scope ofCARG- 2020 as a pan-cancer candidate, we also showthatCARG-2020 works in two additional mouse models of melanoma and triple-negative breast cancer. Administration ofCARG-2020 resulted in increased accumulation of CD8+ T lymphocytes in the tumors, and depletion of these T cells results in poor tumor regression mediated by CARG-2020. Overall, our study shows a broad-spectrum efficacy ofCARG-2020 in solid tumors and demonstrates the potential ofCARG-2020 to be developed as a clinical candidate for the treatment of multiple human cancers that are surgically accessible.  \nKeywords Oncolytic virus, Cancer immunotherapy, Interleukin-12, Interleukin-17, PD-L1  \nViral vectors have been explored for the treatment of cancers in the past decades and have had limited success1. There are only two FDA-approved oncolytic viral therapies in the US. First, T-VEC, derived from type 1 herpes simplex virus carrying the granulocyte macrophage colony-stimulating factor (GM-CSF), is used for the treatment of metastatic melanoma2. Second, a more recent success highlights the use of non-replicative adenovirus to deliver human interferon a-2b through an intravesical route for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer3. Multiple novel oncolytic viral agents are under development, with many carrying immune-modulating payloads, such as GM-CSF, to enhance anti-tumor immunity1,4. In addition, oncolytic viral therapies may be administered alone or in combination with other therapies for cancers, notably immune checkpoint inhibitors4. As more pathways involved in the activation and persistence of anti-cancer immunity are discovered, there is a general trend to target multiple pathways simultaneously to enhance the efficacy of cancer immunotherapies. Another avenue to increase the efficacy of oncolytic viral agents is systemic delivery which is also an area under active investigation1,4.  \nIn our recent studies, we combined the oncolytic virus-like vesicle (VLV) platform with immunomodulatory payloads targeting IL-12, IL-17, and PD-L1 pathways simultaneously. VLV is a self-amplifying RNA replicon vector designed by combining Semliki Forest virus (SFV) RNA-dependent polymerase and vesicular stomatitis virus glycoprotein (VSV-G)5–7. Additionally, VLVs can co-express different payloads from multiple subgenomic regions8–11. Among the payloads of CARG-2020, IL-12 is a heterodimeric protein containing p35 and p40 subunits that potently stimulates Th1 immunity12, 13. Following IL-12 stimulation, antigen-engaged CD4+ T cells differentiate into IFN-γ producing T helper type 1 cells12. These T cells in turn aid anti-cancer immunity by activating tumor infiltrating CD8+ T cells, NK cells, dendritic cells, among others14. This cytokine has been explored for the treatment of cancers, but its clinical use through s","cbCaid0B30xI8Zgf","https://ap.wps.com/l/cbCaid0B30xI8Zgf","pdf",5744426,14,"English","# Background\n## Engineered oncolytic viruses and immune modulation\n# Study Rationale and Design\n## VLV platform and CARG-2020 payloads\n# Mechanistic Basis\n## IL-12–driven T helper 1 responses\n## IL-17RA antagonism\n## PD-L1 shRNA targeting the PD-1 axis\n# Experimental Findings (reported)\n## Systemic delivery and tumor control in mouse models","[{\"question\":\"What is CARG-2020 and what immune pathways does it target?\",\"answer\":\"CARG-2020 is an engineered trivalent oncolytic viral construct that expresses IL-12 and uses shRNAs to inhibit IL-17RA signaling and regulate PD-L1 expression, thereby modulating multiple anti-tumor immune pathways.\"},{\"question\":\"How was CARG-2020 administered in the study, and what was the reported effect?\",\"answer\":\"CARG-2020 was delivered systemically via the intravenous route. The study reports successful control of tumor growth in mouse models, including melanoma and triple-negative breast cancer, in addition to colorectal cancer.\"},{\"question\":\"Why do CD8+ T lymphocytes matter for CARG-2020 efficacy?\",\"answer\":\"Administration of CARG-2020 increases accumulation of CD8+ T lymphocytes in tumors. Depleting these T cells results in poor tumor regression, indicating CD8+ T cells are important for the therapeutic effect.\"}]","CARG-2020 targets IL-12, IL-17, and PD-L1 pathways to effectively treat melanoma and breast cancer | PDF",1790184443,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9670d556b6667d65bf5bf9a8b04cd93d.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78e424ba597812469a544de8cb73f734.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13983318ff4279838b5fd1b79ae3496c.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/333176a4b56cec714831eca6773e3930.webp",980,1287]